NCT02695160View on ClinicalTrials.gov

Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 15, 2016

Primary Completion Date

April 19, 2021

Study Completion Date

April 19, 2021

Conditions
Hemophilia B
Interventions
BIOLOGICAL

SB-FIX

Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.

Trial Locations (1)

20007

Georgetown University Medical Center, Washington D.C.

Sponsors
All Listed Sponsors
lead

Sangamo Therapeutics

INDUSTRY